This prospective, single centre, open –label study assessed the efficacy, efficiency and tolerability of topical
recombinant human platelet –derived growth factor (rhPDGF) in the treatment of chronic ulcers at sites other than the foot
in 4 patients with diabetes mellitus. RhPDGF gel 0.01% was applied once daily to the target ulcer in these patients.
Efficacy was assessed in terms of ulcer size reduction and efficiency as time to complete healing. Safety was assessed in
terms of incidence of adverse events. All ulcers healed completely, of which 2 healed within 2 weeks, 1 by 4 weeks, and 1
by 8 weeks.